Treatment by Postcode: The NHS Rationing Crisis That Nobody in Government Will Admit Exists
The Waiting Room That Never Empties
In January 2025, NHS England published its latest performance figures. The data confirmed what patients and clinicians have known for some time: the NHS waiting list, while fractionally reduced from its 7.8 million peak, remains at a level that would have been considered a national emergency in any previous era of British healthcare. Hundreds of thousands of patients have been waiting more than a year for treatment. Tens of thousands have waited more than eighteen months.
But the waiting list figures, grim as they are, tell only part of the story. The part that receives far less attention — and that the government has a strong institutional incentive to keep quiet — is what is happening to the treatments that patients never get referred for in the first place.
Rationing in Plain Sight
Across England, NHS Integrated Care Boards — the commissioning bodies that replaced Clinical Commissioning Groups in 2022 — have been quietly restricting access to treatments through a mechanism known as Individual Funding Requests, or through the simple expedient of removing procedures from their standard commissioning frameworks. Treatments that were routinely available on the NHS a decade ago are now classified as 'low clinical value' or subject to prior authorisation criteria that many patients cannot meet.
The British Medical Association has documented this process with increasing alarm. A 2023 survey of GPs found that the majority reported being unable to refer patients for treatments they clinically judged to be necessary, either because the treatment had been restricted by their ICB or because waiting times made referral functionally meaningless. Orthopaedic procedures, some ophthalmology treatments, certain dermatological interventions, and a range of mental health services have all been subject to restriction in various parts of the country.
None of this is announced. There is no parliamentary statement, no press release, no democratic accountability. The rationing happens through the opaque commissioning decisions of bodies that most patients have never heard of and cannot meaningfully influence.
The Private Sector's Perfect Storm
Into this vacuum, the private healthcare sector has expanded with remarkable speed. Nuffield Health, Spire Healthcare, and a growing number of independent sector treatment centres have reported strong revenue growth over the past three years, driven substantially by patients who have concluded — correctly — that waiting for NHS treatment is not a viable option.
Private health insurance premiums have risen sharply in response to increased demand. According to data from the Association of British Insurers, the number of people with private medical insurance in the UK has been growing, with many employers expanding coverage as a recruitment benefit. This is, in one sense, a rational market response to NHS capacity constraints. In another sense, it is the institutionalisation of a two-tier system.
The political economy here deserves scrutiny. NHS trusts, under financial pressure, have been actively encouraged to use their spare capacity to treat private patients — a practice that generates income for the trust but that critics argue diverts clinical resource away from NHS patients. The NHS's private patient income has grown substantially over the past decade. The logic is superficially appealing: private revenue subsidises NHS care. The reality, as documented by researchers at the King's Fund and the Health Foundation, is considerably more complicated, with evidence that private patient activity can displace NHS activity rather than supplement it.
Management Consultants and the Language of Efficiency
One of the more revealing features of the NHS rationing debate is the vocabulary used to obscure it. Treatments are not rationed — they are 'decommissioned'. Waiting lists are not a consequence of underfunding — they reflect a need for 'pathway redesign'. The involvement of management consultants in NHS decision-making, at enormous cost to the public purse, has produced a layer of corporate language that insulates these decisions from democratic challenge.
The Health Service Journal has reported extensively on the scale of consultancy spending within NHS England and individual trusts. Firms including McKinsey, KPMG, and Deloitte have been paid hundreds of millions of pounds over the past decade to advise on NHS reform — often, critics note, recommending models of service delivery that create opportunities for the private sector interests these same firms also advise. The conflict of interest is structural and largely unaddressed.
The Strongest Defence — and Why It Is Insufficient
The government's position, and that of NHS England's leadership, is that the health service must live within its means, that not every treatment can be provided regardless of cost-effectiveness, and that prioritisation based on clinical evidence is a legitimate and necessary function of a publicly funded system. NICE — the National Institute for Health and Care Excellence — exists precisely to make these assessments, and its cost-effectiveness thresholds represent a genuine attempt to allocate limited resources rationally.
This is a serious argument, and it should not be dismissed. Resources are finite. Prioritisation is real. A health system that tried to fund every conceivable intervention regardless of cost-effectiveness would rapidly become unsustainable.
But this argument is being misused. The current pattern of rationing is not primarily driven by NICE assessments of clinical evidence. It is driven by financial pressure on ICBs that have been systematically underfunded relative to the demand they face. The King's Fund has estimated that NHS funding as a share of GDP remains below the European average. The Health Foundation has documented a decade of real-terms funding constraint that has left the service structurally unable to meet demand. When ICBs restrict treatments, they are not making refined clinical judgements — they are making financial decisions dressed in clinical language.
Who Cannot Afford to Go Private?
The human geography of NHS rationing is not neutral. The patients who are most severely affected by waiting lists and treatment restrictions are those who cannot afford to circumvent the system privately. A middle-class professional with employer-funded health insurance can access a hip replacement within weeks. A care worker in the same clinical condition, without private cover and without the savings to self-fund, joins a waiting list that may stretch beyond a year — and risks the deterioration, loss of employment, and mental health consequences that prolonged pain and immobility produce.
This is not an incidental feature of the current situation. It is the mechanism by which class inequality is reproduced through the healthcare system. The NHS was founded on the explicit principle that access to care should be determined by clinical need, not ability to pay. That principle is being eroded — not through a single dramatic policy decision, but through a thousand quiet commissioning choices, each individually defensible, collectively corrosive.
What the Political Moment Demands
The Wes Streeting era at the Department of Health has been characterised by a stated commitment to reform, a willingness to challenge NHS orthodoxies, and a rhetorical openness to private sector involvement that has alarmed many on the left. Whether the reforms being pursued will genuinely strengthen the NHS or accelerate its fragmentation remains the central contested question of health policy in this Parliament.
What is not in doubt is that the current trajectory — underfunded public provision, quietly expanding rationing, and a growing private market for those who can afford it — represents a fundamental departure from the founding principles of the health service. If it continues, the NHS risks becoming, within a generation, what its opponents have always wanted it to be: a safety net for the poor, rather than a universal service for everyone.
That outcome is not inevitable. But preventing it requires politicians willing to name what is happening, fund the service adequately, and resist the managed decline that has been dressed up, for too long, as modernisation.
